Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Cognition Therapeutics Inc has a consensus price target of $6.25 based on the ratings of 7 analysts. The high is $14 issued by Rodman & Renshaw on July 2, 2024. The low is $1.5 issued by B. Riley Securities on December 19, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co. on May 27, 2025, May 8, 2025, and March 24, 2025, respectively. With an average price target of $4 between HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co., there's an implied 1170.24% upside for Cognition Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/27/2025 | Buy Now | 852.68% | HC Wainwright & Co. | Raghuram Selvaraju44% | $5 → $3 | Maintains | Buy | Get Alert |
05/08/2025 | Buy Now | 1170.24% | Chardan Capital | Daniil Gataulin51% | $8 → $4 | Maintains | Buy | Get Alert |
03/24/2025 | Buy Now | 1487.81% | HC Wainwright & Co. | Raghuram Selvaraju44% | $6 → $5 | Maintains | Buy | Get Alert |
03/21/2025 | Buy Now | 2440.49% | Chardan Capital | Daniil Gataulin51% | $11 → $8 | Maintains | Buy | Get Alert |
02/26/2025 | Buy Now | 3393.17% | Chardan Capital | Daniil Gataulin51% | $11 → $11 | Maintains | Buy | Get Alert |
12/19/2024 | Buy Now | 376.34% | B. Riley Securities | Mayank Mamtani71% | $1 → $1.5 | Upgrade | Neutral → Buy | Get Alert |
12/19/2024 | Buy Now | 3393.17% | Chardan Capital | Daniil Gataulin51% | $11 → $11 | Maintains | Buy | Get Alert |
12/19/2024 | Buy Now | 1805.37% | HC Wainwright & Co. | Raghuram Selvaraju44% | $5 → $6 | Maintains | Buy | Get Alert |
11/27/2024 | Buy Now | 1487.81% | HC Wainwright & Co. | Raghuram Selvaraju44% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
11/15/2024 | Buy Now | 3393.17% | Chardan Capital | Daniil Gataulin51% | $11 → $11 | Maintains | Buy | Get Alert |
11/04/2024 | Buy Now | 1487.81% | HC Wainwright & Co. | Raghuram Selvaraju44% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
10/31/2024 | Buy Now | 3393.17% | Chardan Capital | Daniil Gataulin51% | $11 → $11 | Maintains | Buy | Get Alert |
08/12/2024 | Buy Now | 1487.81% | HC Wainwright & Co. | Raghuram Selvaraju44% | $7 → $5 | Maintains | Buy | Get Alert |
08/06/2024 | Buy Now | 217.56% | B. Riley Securities | Mayank Mamtani71% | $5 → $1 | Downgrade | Buy → Neutral | Get Alert |
08/01/2024 | Buy Now | 2122.93% | HC Wainwright & Co. | Raghuram Selvaraju44% | $10 → $7 | Maintains | Buy | Get Alert |
07/30/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan69% | — | Downgrade | Overweight → Neutral | Get Alert |
07/02/2024 | Buy Now | 4345.86% | Rodman & Renshaw | Elemer Piros54% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
06/06/2024 | Buy Now | 3393.17% | Chardan Capital | Daniil Gataulin51% | → $11 | Initiates | → Buy | Get Alert |
05/29/2024 | Buy Now | 3075.61% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $10 | Initiates | → Buy | Get Alert |
03/28/2024 | Buy Now | 1487.81% | B. Riley Securities | Mayank Mamtani71% | → $5 | Reiterates | Buy → Buy | Get Alert |
03/27/2024 | Buy Now | 2758.05% | Oppenheimer | Jay Olson60% | $9 → $9 | Maintains | Outperform | Get Alert |
08/14/2023 | Buy Now | 1805.37% | Ladenburg Thalmann | Aydin Huseynov33% | $10 → $6 | Maintains | Buy | Get Alert |
05/09/2023 | Buy Now | 2758.05% | Oppenheimer | Jay Olson60% | → $9 | Reiterates | → Outperform | Get Alert |
03/24/2023 | Buy Now | 2758.05% | Oppenheimer | Jay Olson60% | → $9 | Reiterates | → Outperform | Get Alert |
09/29/2022 | Buy Now | 3710.73% | Cantor Fitzgerald | Charles Duncan69% | → $12 | Initiates | → Overweight | Get Alert |
The latest price target for Cognition Therapeutics (NASDAQ:CGTX) was reported by HC Wainwright & Co. on May 27, 2025. The analyst firm set a price target for $3.00 expecting CGTX to rise to within 12 months (a possible 852.68% upside). 17 analyst firms have reported ratings in the last year.
The latest analyst rating for Cognition Therapeutics (NASDAQ:CGTX) was provided by HC Wainwright & Co., and Cognition Therapeutics maintained their buy rating.
The last upgrade for Cognition Therapeutics Inc happened on December 19, 2024 when B. Riley Securities raised their price target to $1.5. B. Riley Securities previously had a neutral for Cognition Therapeutics Inc.
The last downgrade for Cognition Therapeutics Inc happened on August 6, 2024 when B. Riley Securities changed their price target from $5 to $1 for Cognition Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cognition Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cognition Therapeutics was filed on May 27, 2025 so you should expect the next rating to be made available sometime around May 27, 2026.
While ratings are subjective and will change, the latest Cognition Therapeutics (CGTX) rating was a maintained with a price target of $5.00 to $3.00. The current price Cognition Therapeutics (CGTX) is trading at is $0.31, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.